Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This paper summarises the study protocol for the randomised controlled trial of iodine supplementation in preterm infants. Iodine is essential for the synthesis of thyroxine, and thyroxine is essential for normal brain development in utero and for the first 2-3 years of life. The recommended iodine intake in parenteral nutrition regimens is 1 μg/kg/day and commercially available parenteral solutions for infants reflect these recommendations. In the absence of other iodine sources, infants are vulnerable to negative iodine balance and insufficiency. As many preterm infants are fed parenterally for prolonged periods with solutions which have been shown to be iodine-deficient, the I2S2 Trial was designed to establish whether iodine supplementation of preterm infants benefits neurodevelopment.

Original publication

DOI

10.1159/000358247

Type

Journal article

Journal

Neonatology

Publication Date

2014

Volume

105

Pages

282 - 289

Keywords

Age Factors, Child Development, Clinical Protocols, Dietary Supplements, Gestational Age, Humans, Infant Nutritional Physiological Phenomena, Infant, Extremely Premature, Infant, Newborn, Nervous System, Nutritional Status, Parenteral Nutrition, Recommended Dietary Allowances, Research Design, Sodium Iodide, Time Factors, Treatment Outcome